
Jim Cramer highlighted Cardinal Health as a stock well-suited for current market conditions due to its role in pharmaceutical distribution and healthcare manufacturing. The company reported strong fiscal Q1 2027 results, beating earnings and revenue expectations, with specialty drug growth and contract renewals boosting confidence. Despite thin margins and regulatory risks, Cardinal Health offers steady profits, a low beta indicating defensive qualities, and ongoing share buybacks. Investors should watch for upcoming earnings moderation and drug pricing policy changes, but the stock remains a durable option for long-term growth at a 22x forward P/E ratio.
Cardinal Health (CAH) trades at USD 273.92 with a 1-day gain of 0.58% on Pluang as of Nov 20, 2026 22:02 WIB, reflecting steady investor interest. The stock's market cap stands at $62.95 billion with a dividend yield of 0.76%, while all Pluang orders are buys, indicating strong demand. This aligns with Jim Cramer's view of Cardinal Health as a resilient stock for current market conditions.